AR092532A1 - Etanercept correctamente plegado de alta pureza y excelente rendimiento - Google Patents
Etanercept correctamente plegado de alta pureza y excelente rendimientoInfo
- Publication number
- AR092532A1 AR092532A1 ARP130103250A ARP130103250A AR092532A1 AR 092532 A1 AR092532 A1 AR 092532A1 AR P130103250 A ARP130103250 A AR P130103250A AR P130103250 A ARP130103250 A AR P130103250A AR 092532 A1 AR092532 A1 AR 092532A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- folded
- correctly folded
- etanercept
- mixed mode
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Método de cromatografía de modo mixto para separar las conformaciones correctamente plegadas de las incorrectamente plegadas de una proteína dada. El método es muy eficaz en la separación de etanercept correctamente plegado del etanercept incorrectamente plegado y de agregados con rendimientos comercialmente atractivos que permiten obtener preparaciones de etanercept de una muy alta pureza en términos de etanercept correctamente plegado versus etanercept incorrectamente plegado. La solicitud está dirigida además a preparaciones de proteínas y formulaciones que comprenden proteínas correctamente plegadas obtenidas usando los métodos de la presente, y métodos de tratamiento que emplean las preparaciones de gran pureza obtenidas del método de modo mixto. Reivindicación 1: Un método de cromatografía de modo mixto para separar una proteína correctamente plegada de una proteína incorrectamente plegada, que comprende los pasos de: (a) unir una primera mezcla de proteínas que comprende ambas conformaciones correctamente plegada e incorrectamente plegada de una proteína dada con una resina de cromatografía de modo mixto que tiene porciones de intercambio iónico y porciones hidrofóbicas; (b) eluir la proteína correctamente plegada de la resina de modo mixto para obtener una segunda mezcla de proteínas que Comprende una mayor proporción de proteína correctamente plegada que la primera mezcla de proteínas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261699552P | 2012-09-11 | 2012-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR092532A1 true AR092532A1 (es) | 2015-04-22 |
Family
ID=50233493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130103250A AR092532A1 (es) | 2012-09-11 | 2013-09-11 | Etanercept correctamente plegado de alta pureza y excelente rendimiento |
Country Status (32)
Country | Link |
---|---|
US (6) | US20140072560A1 (es) |
EP (1) | EP2895188B1 (es) |
JP (3) | JP2015533797A (es) |
KR (2) | KR102133699B1 (es) |
CN (2) | CN110051823A (es) |
AR (1) | AR092532A1 (es) |
AU (2) | AU2013315750B9 (es) |
BR (1) | BR112015005161A2 (es) |
CA (1) | CA2882551A1 (es) |
CL (1) | CL2015000572A1 (es) |
CO (1) | CO7400876A2 (es) |
CY (1) | CY1120062T1 (es) |
DK (1) | DK2895188T3 (es) |
DO (1) | DOP2015000055A (es) |
EA (1) | EA031324B1 (es) |
EC (1) | ECSP15014138A (es) |
ES (1) | ES2657377T3 (es) |
HR (1) | HRP20180182T1 (es) |
HU (1) | HUE036524T2 (es) |
IL (2) | IL237311B (es) |
IN (1) | IN2015KN00452A (es) |
LT (1) | LT2895188T (es) |
MX (2) | MX360044B (es) |
NO (1) | NO2972131T3 (es) |
PE (2) | PE20150996A1 (es) |
PL (1) | PL2895188T3 (es) |
PT (1) | PT2895188T (es) |
RS (1) | RS57013B1 (es) |
SG (1) | SG11201501460RA (es) |
SI (1) | SI2895188T1 (es) |
TW (2) | TWI716649B (es) |
WO (1) | WO2014043103A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2610839C (en) | 2005-06-14 | 2019-06-25 | Amgen Inc. | Self-buffering protein formulations |
MX2014004725A (es) | 2011-10-18 | 2015-02-05 | Coherus Biosciences Inc | Formulaciones de etanercept estabilizadas con aminoacidos. |
US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
CN110051823A (zh) * | 2012-09-11 | 2019-07-26 | 科荣生生物科学公司 | 高纯度和优异产量的正确折叠的依那西普 |
MX2016016318A (es) * | 2014-06-13 | 2017-06-12 | Lupin Atlantis Holdings Sa | Proceso para la purificacion de la proteina de fusion. |
EP2975050B1 (en) * | 2014-07-18 | 2019-05-29 | Sandoz Ag | Quantification of misfolded TNFR2:Fc |
BR112017014224A2 (pt) | 2014-12-31 | 2018-03-06 | Lg Chem, Ltd. | método para a preparação de proteína de fusão fc-tnfr que contém teor alvo de impurezas |
KR20170138426A (ko) | 2015-03-13 | 2017-12-15 | 삼성바이오에피스 주식회사 | 항-tnf-알파 폴리펩티드 조성물 및 그 용도 |
KR20180083409A (ko) * | 2015-11-18 | 2018-07-20 | 메르크 파텐트 게엠베하 | 이온 교환 크로마토그래피에서의 개선된 단백질 분리 |
CN108350027A (zh) * | 2015-11-18 | 2018-07-31 | 默克专利股份公司 | 用于改进的蛋白质分离的相反的pH-盐梯度 |
TWI798179B (zh) * | 2016-06-17 | 2023-04-11 | 美商建南德克公司 | 多特異性抗體之純化 |
CN109982685B (zh) * | 2016-10-21 | 2022-03-11 | 美国安进公司 | 药物配制品及其制备方法 |
MX2019011343A (es) * | 2017-03-24 | 2019-11-18 | Council Scient Ind Res | Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes. |
US11253569B2 (en) | 2018-05-03 | 2022-02-22 | Seattle Children's Hospital | Methods of treating Kawasaki Disease |
CN112876567A (zh) * | 2019-11-29 | 2021-06-01 | 广东菲鹏制药股份有限公司 | Fc融合蛋白及其纯化方法 |
WO2022195505A1 (en) * | 2021-03-16 | 2022-09-22 | Kashiv Biosciences, Llc | Novel formulation of fusion protein |
WO2022234412A1 (en) * | 2021-05-03 | 2022-11-10 | Lupin Limited | A process for purification of fc-fusion proteins |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
ATE236249T1 (de) | 1989-09-12 | 2003-04-15 | Hoffmann La Roche | Tfn-bindende proteine |
IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
ATE169030T1 (de) | 1990-06-28 | 1998-08-15 | Hoechst Ag | Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung |
JPH07504203A (ja) | 1992-09-15 | 1995-05-11 | イミュネックス・コーポレーション | 腫瘍壊死因子アンタゴニストを用いるtnf−依存性炎症の治療方法 |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
US7294481B1 (en) | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
US20010021380A1 (en) | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
EP1171148A2 (en) | 1999-04-19 | 2002-01-16 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical desorders |
BR0108193A (pt) | 2000-02-10 | 2003-02-25 | Wyeth Corp | Processo para tratamento ou inibição de dano celular ou morte celular |
EP1314437B1 (en) | 2000-08-11 | 2014-06-25 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing preparations |
WO2002068455A2 (en) | 2001-02-23 | 2002-09-06 | Immunex Corporation | Efficient recovery of correctly refolded proteins |
PT1946776T (pt) | 2002-02-27 | 2017-03-17 | Immunex Corp | Composição de tnfr-fc estabilizada compreendendo arginina |
WO2004017955A1 (en) * | 2002-08-22 | 2004-03-04 | Vasopharm Biotech Gmbh | L-arginine containing pharmaceutical composition |
US20040115263A1 (en) | 2002-08-26 | 2004-06-17 | Robertson David W. | Use of bupropion for treating restless legs syndrome |
WO2004075918A1 (en) | 2003-02-28 | 2004-09-10 | Ares Trading S.A. | Liquid formulations of tumor necrosis factor-binding proteins |
WO2004082715A1 (ja) | 2003-03-20 | 2004-09-30 | Eisai Co., Ltd. | 炎症性腸疾患治療剤としての併用医薬 |
US7276477B2 (en) | 2003-08-01 | 2007-10-02 | Amgen Inc. | Crystals of etanercept and methods of making thereof |
EP2407470A3 (en) | 2003-10-14 | 2015-06-10 | F. Hoffmann-La Roche Ltd. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication |
WO2005082483A1 (en) * | 2004-02-27 | 2005-09-09 | Ge Healthcare Bio-Sciences Ab | A process for the purification of antibodies |
JP5554466B2 (ja) | 2004-03-01 | 2014-07-23 | 味の素株式会社 | 抗ヒトTNF−α抗体活性低下抑制剤 |
CN104388324A (zh) | 2004-03-05 | 2015-03-04 | 帝斯曼知识产权资产管理有限公司 | 用于通过连续灌注和交互切向流来培养细胞的方法 |
US20070196364A1 (en) | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
AU2006244014B2 (en) | 2005-05-10 | 2011-03-17 | Biogen Ma Inc. | Treating and evaluating inflammatory disorders |
US8945543B2 (en) | 2005-06-10 | 2015-02-03 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
TW200738261A (en) | 2005-12-20 | 2007-10-16 | Bristol Myers Squibb Co | Stable protein formulations |
EP1962907A2 (en) | 2005-12-21 | 2008-09-03 | Wyeth a Corporation of the State of Delaware | Protein formulations with reduced viscosity and uses thereof |
WO2007092772A2 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Inc. | Protein formulations |
EA015992B1 (ru) | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
US20080003220A1 (en) | 2006-04-21 | 2008-01-03 | Amgen, Inc. | Buffering agents for biopharmaceutical formulations |
EP2081553B1 (en) | 2006-10-06 | 2020-08-12 | Amgen Inc. | Stable antibody formulations |
JP5623743B2 (ja) | 2006-10-20 | 2014-11-12 | アムジエン・インコーポレーテツド | 安定なポリペプチド製剤 |
MX2009004519A (es) | 2006-11-03 | 2009-05-12 | Wyeth Corp | Sustancias que inhiben la glucolisis en un cultivo de celulas. |
EP2129401B8 (en) | 2006-12-21 | 2020-01-15 | Amgen Inc. | Stable buffered formulations containing polypeptides |
US7691980B2 (en) * | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
PT2115126E (pt) | 2007-03-02 | 2015-08-24 | Wyeth Llc | Utilização de cobre e glutamato na cultura de células para a produção de polipeptídeos |
EP2014760A1 (en) | 2007-06-13 | 2009-01-14 | CMC Biopharmaceuticals A/S | A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process |
EP3461500A1 (en) | 2007-06-14 | 2019-04-03 | Biogen MA Inc. | Natalizumab antibody formulations |
JP5840364B2 (ja) | 2007-11-30 | 2016-01-06 | アッヴィ バイオテクノロジー リミテッド | タンパク質製剤及びその製造方法 |
MX2010009398A (es) | 2008-02-29 | 2010-11-12 | Biogen Idec Inc | Proteinas de fusion de inmunoglobulinas purificadas y los metodos para su purificacion. |
US9238810B2 (en) * | 2008-06-05 | 2016-01-19 | Affibody Ab | Polypeptide |
WO2011015926A1 (en) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein |
ES2817802T3 (es) | 2009-08-07 | 2021-04-08 | Emd Millipore Corp | Métodos para purificar una proteína objetivo de una o más impurezas en una muestra |
JP5930542B2 (ja) | 2009-08-11 | 2016-06-08 | ジェネンテック, インコーポレイテッド | グルタミンフリー細胞培養培地におけるタンパク質の生産 |
WO2011049798A1 (en) * | 2009-10-20 | 2011-04-28 | Merck Sharp & Dohme Corp. | Use of mixed mode chromatography for the capture and purification of basic antibody products |
WO2011079308A2 (en) | 2009-12-23 | 2011-06-30 | Emergent Product Development Seattle, Llc | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
USRE48864E1 (en) | 2010-04-26 | 2021-12-28 | Novartis Ag | Cell culture medium |
RU2600847C2 (ru) * | 2010-05-10 | 2016-10-27 | Интас Биофармасьютикалс Лимитед | Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина |
WO2012013980A1 (en) | 2010-07-30 | 2012-02-02 | Arecor Limited | Stabilized aqueous antibody compositions |
JP2013535981A (ja) | 2010-08-20 | 2013-09-19 | ワイス・エルエルシー | 成長因子不含適合細胞の細胞培養 |
CA2807895A1 (en) | 2010-08-31 | 2012-03-08 | Friesland Brands B.V. | Culture medium for eukaryotic cells |
SG189872A1 (en) * | 2010-10-11 | 2013-06-28 | Abbvie Inc | Processes for purification of proteins |
JP5996631B2 (ja) | 2011-04-20 | 2016-09-21 | サンド・アクチエンゲゼルシヤフト | TNFR:Fc融合タンパク質の安定した医薬液剤 |
UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
KR102061355B1 (ko) | 2011-07-01 | 2019-12-31 | 바이오젠 엠에이 인코포레이티드 | 아르기닌-없는 tnfr : fc-융합 폴리펩티드 조성물 및 이용 방법 |
PL2726600T3 (pl) | 2011-07-01 | 2017-08-31 | Amgen Inc. | Hodowla ssaczych komórek |
AU2012282960A1 (en) * | 2011-07-08 | 2014-01-16 | Merck Sharp & Dohme Corp. | Method for purifying Fc-fusion protein |
US9279014B2 (en) | 2011-08-17 | 2016-03-08 | Ares Trading S.A. | Methods for preparing an active TNFR-Fc fusion protein |
MX2014004725A (es) | 2011-10-18 | 2015-02-05 | Coherus Biosciences Inc | Formulaciones de etanercept estabilizadas con aminoacidos. |
US10493151B2 (en) * | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
CN104661651A (zh) * | 2012-07-09 | 2015-05-27 | 科荣生生物科学公司 | 表现出不溶性微粒显著减少的依那西普制剂 |
CN110051823A (zh) * | 2012-09-11 | 2019-07-26 | 科荣生生物科学公司 | 高纯度和优异产量的正确折叠的依那西普 |
EP3879334B1 (en) * | 2014-07-31 | 2023-11-29 | Mtt Innovation Incorporated | Numerical approaches for free-form lensing: area parameterization free-form lensing |
US20160108634A1 (en) * | 2014-10-16 | 2016-04-21 | Ronald Uphold | Pool Cover Hanger Device |
-
2013
- 2013-09-10 CN CN201811633164.2A patent/CN110051823A/zh active Pending
- 2013-09-10 SI SI201330936T patent/SI2895188T1/en unknown
- 2013-09-10 SG SG11201501460RA patent/SG11201501460RA/en unknown
- 2013-09-10 IN IN452KON2015 patent/IN2015KN00452A/en unknown
- 2013-09-10 AU AU2013315750A patent/AU2013315750B9/en not_active Ceased
- 2013-09-10 JP JP2015531311A patent/JP2015533797A/ja active Pending
- 2013-09-10 HU HUE13838016A patent/HUE036524T2/hu unknown
- 2013-09-10 MX MX2015003090A patent/MX360044B/es active IP Right Grant
- 2013-09-10 LT LTEP13838016.7T patent/LT2895188T/lt unknown
- 2013-09-10 EA EA201590542A patent/EA031324B1/ru unknown
- 2013-09-10 WO PCT/US2013/058994 patent/WO2014043103A1/en active Application Filing
- 2013-09-10 CN CN201380058650.5A patent/CN104902914B/zh not_active Expired - Fee Related
- 2013-09-10 ES ES13838016.7T patent/ES2657377T3/es active Active
- 2013-09-10 BR BR112015005161A patent/BR112015005161A2/pt not_active Application Discontinuation
- 2013-09-10 RS RS20180095A patent/RS57013B1/sr unknown
- 2013-09-10 PE PE2015000316A patent/PE20150996A1/es unknown
- 2013-09-10 KR KR1020157009386A patent/KR102133699B1/ko active IP Right Grant
- 2013-09-10 PE PE2019002512A patent/PE20200607A1/es unknown
- 2013-09-10 PT PT138380167T patent/PT2895188T/pt unknown
- 2013-09-10 KR KR1020207019733A patent/KR102250937B1/ko active IP Right Grant
- 2013-09-10 EP EP13838016.7A patent/EP2895188B1/en active Active
- 2013-09-10 CA CA2882551A patent/CA2882551A1/en active Pending
- 2013-09-10 DK DK13838016.7T patent/DK2895188T3/en active
- 2013-09-10 PL PL13838016T patent/PL2895188T3/pl unknown
- 2013-09-11 AR ARP130103250A patent/AR092532A1/es not_active Application Discontinuation
- 2013-09-11 TW TW106136921A patent/TWI716649B/zh not_active IP Right Cessation
- 2013-09-11 TW TW102132831A patent/TWI609877B/zh not_active IP Right Cessation
- 2013-09-11 US US14/023,736 patent/US20140072560A1/en not_active Abandoned
-
2014
- 2014-03-13 NO NO14719160A patent/NO2972131T3/no unknown
-
2015
- 2015-02-19 IL IL237311A patent/IL237311B/en active IP Right Grant
- 2015-03-06 CL CL2015000572A patent/CL2015000572A1/es unknown
- 2015-03-10 DO DO2015000055A patent/DOP2015000055A/es unknown
- 2015-03-10 MX MX2018012749A patent/MX2018012749A/es unknown
- 2015-04-07 CO CO15076746A patent/CO7400876A2/es unknown
- 2015-04-10 EC ECIEPI201514138A patent/ECSP15014138A/es unknown
-
2017
- 2017-09-29 US US15/720,291 patent/US11001627B2/en active Active
-
2018
- 2018-01-31 HR HRP20180182TT patent/HRP20180182T1/hr unknown
- 2018-02-13 CY CY20181100172T patent/CY1120062T1/el unknown
- 2018-10-10 AU AU2018247244A patent/AU2018247244B2/en not_active Ceased
- 2018-10-11 JP JP2018192476A patent/JP6913066B2/ja active Active
-
2019
- 2019-06-17 US US16/443,514 patent/US10954293B2/en active Active
- 2019-06-17 US US16/443,688 patent/US10947306B2/en active Active
- 2019-06-17 US US16/443,594 patent/US10954294B2/en active Active
- 2019-06-17 US US16/443,721 patent/US10954295B2/en active Active
- 2019-06-18 IL IL267452A patent/IL267452B/en active IP Right Grant
-
2021
- 2021-02-22 JP JP2021025939A patent/JP2021100929A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR092532A1 (es) | Etanercept correctamente plegado de alta pureza y excelente rendimiento | |
CY1123515T1 (el) | Μεθοδοι αγωγης μιας ταυπαθειας | |
CY1125392T1 (el) | Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων | |
CY1123672T1 (el) | Μεθοδοι αγωγης μιας ταυπαθειας | |
CL2018000226A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
CY1121989T1 (el) | Φαρμακοτεχνικες μορφες αντισωματων | |
CO2020001872A2 (es) | Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana | |
BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
EA201892693A1 (ru) | Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3 | |
WO2017180917A3 (en) | Lipid compositions and their uses for intratumoral polynucleotide delivery | |
PE20060816A1 (es) | Proceso para la concentracion de anticuerpos y productos terapeuticos de los mismos | |
EA201890729A1 (ru) | Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками | |
AR099288A1 (es) | Proteínas de fusión de interleucina-10 | |
CO6491045A2 (es) | Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas | |
MX2013013111A (es) | Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma. | |
AR090884A1 (es) | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc | |
EA201791350A9 (ru) | Радиофармацевтические комплексы | |
TR201911082T4 (tr) | K vitaminine bağımlı proteinlerin saflaştırılması için bir işlem. | |
MX2020000288A (es) | Cromatografia. | |
DOP2016000220A (es) | PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS. | |
BR112021019612A2 (pt) | Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa | |
BR112018017174A2 (pt) | conjugados de aminoácido e peptídeo e processo de conjugação | |
CO2023004265A2 (es) | Métodos para reducir el contenido de proteínas de la célula huésped en procesos de purificación de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteínas de la célula huésped | |
CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
BR112012022292A2 (pt) | método para produção da proteína recombinante interferon solúvel sem desnaturação. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |